24/7 Market News- Terns Pharmaceuticals Reports Positive Phase 1 TERN-601 Clinical Trial Results

September 9, 2024

DENVER, Colo., Sep 09, 2024 (247marketnews.com)- Terns Pharmaceuticals (Nasdaq: TERN) reported positive top-line data from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose trial to assess TERN-601’s safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in healthy adults with obesity or overweight.

The clinical trial results showed TERN-601 was well tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration, while 67% of participants lost 5% or more of their baseline body weight at the top dose.

Amy Burroughs, CEO of Terns, commented, “These compelling results underscore TERN-601’s potential to be a class-leading GLP-1R agonist based on its composite profile of initial indications of efficacy, tolerability and manufacturing scalability.

“These data validate the potential of TERN-601 for the treatment of obesity as monotherapy or in combination with agents such as TERN-501, our internally discovered, clinical stage THR-β agonist, or a GIPR modulator from our TERN-800 series. With operational preparations well underway, we look forward to swiftly advancing this promising product candidate into Phase 2 clinical development in 2025.”

Terns Pharmaceuticals plans to initiate the Phase 2 clinical trial in 2025.

Emil Kuriakose, chief medical officer of Terns, added, “We are delighted to demonstrate potent GLP-1R agonism with TERN-601 as its distinct drug properties allowed for sustained target coverage with once-daily dosing and the evaluation of doses up to 740 mg, while being tolerable.

“Importantly, we believe we have successfully identified an optimal range of clinically active, well tolerated doses to take forward in Phase 2 clinical trials, with no new dose range exploration anticipated.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (TERN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.